Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Clinical development spending increased as aleniglipron entered Phase 3, with results expected in the second half of 2028.

Rhea-AI Summary

Structure Therapeutics (GPCR) reported a third-quarter 2026 net loss of $144.757 million while advancing its oral obesity drug trials. The loss widened from $65.712 million a year earlier. Cash, cash equivalents and short-term investments totaled $1.2 billion at September 30, down from $1.3 billion at June 30.

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 are enrolling participants for aleniglipron, with topline results expected in the second half of 2028. Supplementary aleniglipron results are expected in the fourth quarter of 2026. ACCG-2671 single-dose testing showed an approximately six-day half-life and no serious adverse events; multiple-dose testing is underway, with results expected in the first half of 2027.

The company expects current funds to support projected operations and clinical milestones through the end of 2028, excluding additional pre-commercialization costs, including commercial manufacturing.

11 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Aleniglipron Phase 3 trials are enrolling; topline data are expected in the second half of 2028.
• Moderate pointAleniglipron extension results showed up to 16.2% mean weight reduction in the highest dose group at 72 weeks.
• Moderate pointAleniglipron tolerability improved with a 2.5 mg starting dose; adverse-event discontinuation rates were less than 5%.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Current funds are expected to support projected operations and key clinical milestones through the end of 2028.
• Minor point. Forward-looking: it has not happened yet and may not happen.Supplementary aleniglipron results are expected in fourth-quarter 2026 from body composition, diabetes and SWITCH trials.

6 minor points

• Minor pointACCG-2671 single-dose results showed an approximately six-day half-life and no serious adverse events in 31 healthy adults without obesity.
• Minor point. Forward-looking: it has not happened yet and may not happen.ACCG-2671 multiple-dose testing has begun; topline data are expected in the first half of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.ACCG-3535 Phase 1 testing is planned to begin in the fourth quarter of 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Oral amylin/GLP-1 combination testing is expected to begin in 2027.
• Minor pointInterest and other income, net rose to $11.747 million in third-quarter 2026 from $8.183 million a year earlier.
• Minor pointNine-month interest and other income, net increased to $38.053 million in 2026 from $26.688 million in 2025.

Negative

• Moderate pointThird-quarter net loss widened to $144.757 million in 2026 from $65.712 million in 2025.
• Minor pointThird-quarter research and development expenses increased to $134.552 million in 2026 from $58.989 million in 2025.
• Minor pointThird-quarter general and administrative expenses increased to $21.781 million in 2026 from $14.798 million in 2025.
• Minor pointCash, cash equivalents and short-term investments declined to $1.2 billion at September 30 from $1.3 billion at June 30.
• Minor point. Forward-looking: it has not happened yet and may not happen.Funding runway excludes additional pre-commercialization costs, including commercial manufacturing.

3 minor points

• Minor pointNine-month net loss widened to $326.884 million in 2026 from $174.206 million in 2025.
• Minor pointNine-month research and development expenses increased to $301.116 million in 2026 from $156.566 million in 2025.
• Minor pointNine-month general and administrative expenses increased to $63.226 million in 2026 from $43.983 million in 2025.

News Explained

The release cites September 2026 results from the Phase 2b ACCESS extension: the highest-dose group had up to 16.2% mean body-weight reduction at 72 weeks, while fewer than 5% discontinued because of treatment-emergent adverse events; these are extension-study results, not Phase 3 findings.

Key Figures

Cash, cash equivalents and short-term investments: $1.2 billion R&D expenses: $134.6 million G&A expenses: $21.8 million +5 more

Cash, cash equivalents and short-term investments

$1.2 billion

As of September 30, 2026; expected to fund projected operations and key clinical milestones through end of 2028

R&D expenses

$134.6 million

Q3 2026; compared with $59.0 million in Q3 2025

G&A expenses

$21.8 million

Q3 2026; compared with $14.8 million in Q3 2025

Net loss

$144.8 million

Q3 2026; compared with $65.7 million in Q3 2025

ACCOMPLISH-1 enrollment

Up to 3,600 adults

Phase 3 trial in adults with obesity or overweight and at least one weight-related comorbidity

ACCOMPLISH-2 enrollment

Up to 1,100 adults

Phase 3 trial in adults with obesity or overweight and type 2 diabetes

Mean body-weight reduction

Up to 16.2%

Aleniglipron highest-dose group at 72 weeks in the ACCESS open-label extension

ACCOMPLISH topline data

Second half of 2028

Expected timing for the Phase 3 trials

Previous Earnings Reports

1 past event · Latest: Aug 06

Same Type 1 event

1. Aug 06

   Q2 earnings

   24h Move

   +1.0%

   First patients dosed in Phase 3 ACCOMPLISH; cash was expected to fund milestones through 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1 receptor agonist, pharmacokinetics, pharmacodynamics, placebo-controlled, +1 more

5 terms

glp-1 receptor agonist medical

"aleniglipron (oral small molecule GLP-1 receptor agonist)"

A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.

pharmacokinetics medical

"evaluated the safety, tolerability, pharmacokinetics (PK)"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

pharmacodynamics medical

"and exploratory pharmacodynamics of single doses"

Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.

placebo-controlled medical

"randomized, double-blind, placebo-controlled clinical trials"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

treatment-emergent adverse events medical

"discontinuation rates of less than 5% due to treatment-emergent adverse events"

Events or symptoms that either appear for the first time or get worse after a patient starts a treatment; think of new or intensified side effects that show up once medicine or a medical device is used. Investors watch these closely because they affect whether a therapy can gain regulatory approval, be prescribed widely, or face legal and commercial setbacks—similar to how early customer complaints can sink a new product’s prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of
aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling;
topline data expected in 2H 2028

Additional aleniglipron data expected in Q4 2026
from supplementary body composition, type 2 diabetes and SWITCH studies

Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),
demonstrating a ~6-day half-life and no serious adverse events;
MAD clinical trial dosing underway, with topline data expected in 1H 2027

Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026
expected to fund projected operations and key clinical milestones through 2028

SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio.

“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management,” said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance.”

Dr. Stevens continued, “We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches. Our strategy is to develop differentiated monotherapy and combination medicines to address a range of patient needs. We believe convenient oral administration and scalable manufacturing could help expand access to these potential treatments globally.”

Recent and Upcoming Milestones

Aleniglipron – Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist

The Phase 3 ACCOMPLISH program, which initiated in August 2026, comprises two randomized, double-blind, placebo-controlled clinical trials designed to evaluate the long-term efficacy and safety of aleniglipron and to support global regulatory submissions for chronic weight management.

• ACCOMPLISH-1 is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity. ACCOMPLISH-2 is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM).
• In both trials, participants will receive placebo or one of three aleniglipron maintenance doses (45 mg, 90 mg or 180 mg) following a 2.5 mg starting dose and dose escalation at four-week intervals. Topline data are expected in the second half of 2028.
  
  

In September 2026, the Company reported 72-week results from the ACCESS open-label extension (OLE), a prespecified 36-week extension of the Phase 2b ACCESS clinical trial designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms in ACCESS who continued into the OLE dosed up to 180 mg. Data demonstrated up to 16.2% mean reduction in body weight in the highest dose group at 72 weeks with no observed plateau in the two top dose groups, and improved tolerability with a 2.5 mg starting dose, including treatment discontinuation rates of less than 5% due to treatment-emergent adverse events. 

The Company will present two posters on aleniglipron at The Obesity Society’s Annual Meeting, ObesityWeek^® 2026, taking place November 14–17, 2026, in National Harbor, Maryland. The presentations will cover the ACCESS OLE and the dose-ranging effects of aleniglipron across the ACCESS trials. Both posters are scheduled for presentation on November 15, 2026.

Additional aleniglipron data expected in the fourth quarter of 2026 include topline results from three supplementary clinical trials designed to build on the Phase 2 findings and further characterize aleniglipron’s clinical profile:

• Body composition clinical trial: Results from a 44-week study evaluating the effects of aleniglipron on body fat and overall body composition.
• T2DM clinical trial: Results from a 30-week study in adults living with T2DM and obesity or overweight.
• SWITCH clinical trial: Results evaluating the transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss maintenance over 12 weeks.
  
  

Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists

In September 2026, the Company reported topline results from the single ascending dose (SAD) portion of its Phase 1/2a clinical trial of ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist (DACRA). The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of single doses of 1, 2, 5 or 10 mg of ACCG-2671 or placebo in 31 healthy adult participants without obesity. ACCG-2671 demonstrated a half-life of approximately 6 days. No serious adverse events were reported.

The Company has begun dosing in the 12-week multiple ascending dose (MAD) portion of the Phase 1/2a trial, a randomized, placebo-controlled study evaluating the safety, tolerability and PK of multiple ascending oral doses of ACCG-2671 administered for 84 days across multiple cohorts of participants living with obesity. The trial will evaluate daily and weekly dosing regimens and different titration approaches. It also includes a cohort evaluating ACCG-2671 added to a stable dose of an injectable GLP-1 receptor agonist. Topline data from the MAD portion are expected in the first half of 2027.

The Company plans to initiate a Phase 1 clinical trial of its second oral small molecule DACRA candidate, ACCG-3535, in the fourth quarter of 2026.

In addition, the Company expects to initiate a clinical trial evaluating a combination of oral small molecule amylin and GLP-1 receptor agonists in 2027.

Third Quarter 2026 Financial Highlights

Cash Position: Cash, cash equivalents and short-term investments totaled $1.2 billion as of September 30, 2026, compared to $1.3 billion as of June 30, 2026. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through the end of 2028, including costs related to the Phase 3 registrational program for aleniglipron in chronic weight management, but excludes additional costs related to pre-commercialization activities including commercial manufacturing.

Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were $134.6 million, as compared to $59.0 million for the same period in 2025. The increase in R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses, and employee expenses.

General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $21.8 million, as compared to $14.8 million for the same period in 2025. The increase in G&A expenses was primarily due to increases in employee expenses as the Company expanded its infrastructure to drive and support the growth in operations.

Net Loss: Net loss for the third quarter of 2026 totaled $144.8 million, with non-cash share-based compensation expense of $12.7 million, compared to a net loss of $65.7 million for the same period in 2025, with non-cash share-based compensation expense of $7.5 million.

About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next-generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects, including its research and development activities; the design, initiation, enrollment, conduct, timing and completion of the Company’s clinical trials, including the aleniglipron Phase 3 ACCOMPLISH program, the ACCG-2671 MAD clinical trial, the ACCG-3535 Phase 1 clinical trial and the combination amylin/GLP-1 clinical trial; and the timing of topline, interim or additional data readouts from the aleniglipron Phase 3 ACCOMPLISH program, the ACCG-2671 MAD clinical trial and the aleniglipron body composition, SWITCH and type 2 diabetes clinical trials; the belief that convenient oral administration and scalable manufacturing could help expand access; the Company’s expectation that the aleniglipron ACCOMPLISH clinical trials will support regulatory submissions for aleniglipron in chronic weight management; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects, competitive positioning (including any characterization of a product candidate as potential “best-in-class” or “first-in-class”) and future application of aleniglipron, ACCG-2671, ACCG-3535 and any of the Company’s other investigational compounds; the Company’s ability to support global regulatory submissions for its product candidates and to obtain, maintain and expand regulatory approvals; and the Company’s expectations regarding its cash, cash equivalents and short-term investments and its estimated cash runway, including its ability to fund projected operations and clinical milestones through the end of 2028. In addition, when or if used in this press release, the words and phrases “continue,” “could,” “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “project,” “remain,” “target,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: the risk that topline, interim or preliminary data the Company reports are based on a preliminary analysis of then-available efficacy and safety data, and such data may change following a more comprehensive review of the data related to the applicable clinical trial, and such topline, interim or preliminary data may not accurately reflect the complete or final results of a clinical trial; the preliminary nature of clinical results given the length of the applicable clinical trial and sample size, and the fact that results from earlier clinical trials are not necessarily predictive of future results; potential delays in the commencement, enrollment, conduct or completion of the Company’s planned and ongoing clinical trials, including the Phase 3 ACCOMPLISH program; the risk that clinical trial results may not support further development or regulatory approval of aleniglipron, ACCG-2671, ACCG-3535, or the Company’s other therapeutic candidates; the Company’s ability to obtain and maintain regulatory approval of, and ultimately successfully commercialize, its therapeutic candidates; the effect of competitive products or therapeutic approaches on the commercial value of the Company’s product candidates; the Company’s ability to fund its development activities and achieve its development goals; and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Quarterly Report on Form 10-Q, and other reports the Company has filed or may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investors:
Corey Davis, Ph.D., LifeSci Advisors, LLC, 212-915-2577, cdavis@lifesciadvisors.com
Jen Robinson, Structure Therapeutics Inc., ir@structuretx.com

Media:
Dan Budwick, 1AB, Dan@1abmedia.com

STRUCTURE THERAPEUTICS INC. Condensed Consolidated Statements of Operations (unaudited) (In thousands)
		THREE MONTHS ENDED								NINE MONTHS ENDED
		SEPTEMBER 30,								SEPTEMBER 30,
			2026			2025					2026			2025
Operating expenses:
Research and development		$	134,552			$	58,989			$	301,116			$	156,566
General and administrative			21,781				14,798				63,226				43,983
Total operating expenses			156,333				73,787				364,342				200,549
Loss from operations			(156,333	)			(73,787	)			(364,342	)			(200,549	)
Interest and other income, net			11,747				8,183				38,053				26,688
Loss before provision for income taxes			(144,586	)			(65,604	)			(326,289	)			(173,861	)
Provision for income taxes			171				108				595				345
Net loss		$	(144,757	)		$	(65,712	)		$	(326,884	)		$	(174,206	)

STRUCTURE THERAPEUTICS INC. Condensed Consolidated Balance Sheet Data (unaudited) (In thousands)
		SEPTEMBER 30,			DECEMBER 31,
		2026			2025
Assets
Current assets:
Cash, cash equivalents and short-term investments		$	1,239,975		$	1,446,197
Prepaid expenses and other current assets			35,151			124,106
Total current assets			1,275,126			1,570,303
Property and equipment, net			10,262			6,653
Operating right-of-use assets			6,576			6,245
Other non-current assets			42,455			717
Total assets		$	1,334,419		$	1,583,918
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable		$	33,878		$	13,864
Accrued expenses and other current liabilities			70,463			46,543
Operating lease liabilities, current portion			2,763			2,878
Total current liabilities			107,104			63,285
Operating lease liabilities, net of current portion			4,065			3,609
Other non-current liabilities			1,380			647
Total liabilities			112,549			67,541
Total shareholders’ equity			1,221,870			1,516,377
Total liabilities and shareholders’ equity		$	1,334,419		$	1,583,918

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Structure Therapeutics expect aleniglipron Phase 3 results?

Structure Therapeutics expects topline results from ACCOMPLISH-1 and ACCOMPLISH-2 in the second half of 2028. Both trials are enrolling and are designed to evaluate long-term efficacy and safety and support global regulatory submissions for chronic weight management.

What was Structure Therapeutics' third-quarter 2026 net loss?

Structure Therapeutics reported a $144.757 million net loss for the third quarter of 2026, compared with $65.712 million in the same period of 2025. Non-cash share-based compensation expense was $12.7 million, compared with $7.5 million a year earlier.

Who is being enrolled in Structure Therapeutics' aleniglipron Phase 3 trials?

ACCOMPLISH-1 is enrolling up to 3,600 adults with obesity or overweight and at least one weight-related comorbidity; ACCOMPLISH-2 is enrolling up to 1,100 adults with obesity or overweight and type 2 diabetes. Both trials compare placebo with aleniglipron maintenance doses of 45 mg, 90 mg or 180 mg after a 2.5 mg starting dose and dose escalation at four-week intervals.

What does Structure Therapeutics' ACCG-2671 multiple-dose trial evaluate?

The 12-week multiple ascending dose trial evaluates safety, tolerability and how ACCG-2671 is processed by the body in participants with obesity. It tests daily and weekly dosing regimens and different dose-escalation approaches. A separate cohort evaluates ACCG-2671 added to a stable dose of an injectable GLP-1 receptor agonist.